Lilly provides $1.3 million for US-Russia public-private partnership
This article was originally published in Scrip
Lilly will provide $1.3 million to fund the US–Russia forum in health sciences, a new public-private partnership between healthcare institutions in the two countries. The Foundation for the National Institutes of Health (FNIH), the Fogarty International Center for Advanced Study in the Health Sciences (FIC) and the NIH Clinical Centre launched the project under the framework of the US-Russia presidential commission.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.